Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant.

OBJECTIVE

Evaluate the real-world experience of ubrogepant versus triptans for the acute treatment of migraine among participants switching from an oral triptan.

METHODS

UNIVERSE II was a prospective, longitudinal, survey-based, real-world study conducted in adult Migraine Buddy application users who self-reported a switch from an oral triptan to another oral triptan or ubrogepant. The 4-week study assessed treatment satisfaction, preference for the new treatment or previous triptan, and patient experience with new treatment against previous triptan.

RESULTS

Of 694 participants, 211 were included after screening and accounting for dropouts (triptan, n = 100; ubrogepant, n = 111). At Day 30, significantly greater proportion of the ubrogepant cohort reported satisfaction with treating pain associated with migraine (69.4% vs 42.0%; adjusted odds ratio [OR] = 3.22; [95% confidence interval [CI], 1.80-5.88]; p < 0.001) and alleviating their most bothersome symptom (69.4% vs 42.0%; adjusted OR = 3.10; [95% CI, 1.75-5.60]; p < 0.001) compared with those who switched triptans. The ubrogepant cohort was more likely to prefer their new treatment to their prior triptan (75.7% vs 63.0%; adjusted OR = 1.93; [95% CI, 1.05-3.59]; p = 0.035) and reported better meaningful relief at 2 hours compared to prior triptan (75.7% vs 59.0%; adjusted OR = 2.30; [95% CI, 1.26-4.27]; p = 0.007).

CONCLUSION

This real-world study demonstrated people with migraine who switched from a triptan to ubrogepant reported better outcomes than those who switched to a different triptan.